Best Practice & Research Clinical Rheumatology
Volume 20, Issue 2 , Pages 353-368 , April 2006

Adolescent development and SLE

  • Joyce E. Davidson, BSc, MBChB, MRCP, FRCPCH (Consultant in Paediatric Rheumatology)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 141 201 0867.

References 

  1. Youinou P, Lydyard PM, Mageed RA. B cells underpin lupus immunopathology. Lupus. 2002;11:1–3
  2. Bijl M, Limburg PC, Kallenberg CGM. New insights into the pathogenesis of systemic lupus erythematosus (SLE): the role of apoptosis. The Netherlands Journal of Medicine. 2001;59:66–75
  3. Tucker LB, Menon S, Schaller JG, et al. Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology and outcome. British Journal of Rheumatology. 1995;34:866–872
  4. Wang L-C, Yang Y-H, Lu M-Y, et al. Retrospective analysis of mortality and morbidity of pediatric systemic lupus erythematosus in the past two decades. Journal of Microbiology Immunology and Infection. 2003;36:203–208
  5. Miettunen PM, Ortiz-Alvarez O, Petty RE, et al. Gender and ethnic origin have no effect on longterm outcome of childhood-onset systemic lupus erythematosus. The Journal of Rheumatology. 2004;31:1650–1654
  6. Janwityanujit S, Totemchokchyakarn K, Versertniyom O, et al. Age-related differences on clinical and immunological manifestations of SLE. Asian Pacific Journal of Allergy and Immunology. 1995;13:145–149
  7. Pande I, Sekharan NG, Kailash S, et al. Analysis of clinical and laboratory profile in Indian childhood systemic lupus erythematosus and its comparison with SLE in adults. Lupus. 1993;2:83–87
  8. Stichweh D, Arce E, Pascual V. Update on pediatric systemic lupus erythematosus. Current Opinion in Rheumatology. 2004;16:577–587
  9. Beresford MW, Cleary AG, Sills JA, et al. Cardiopulmonary involvement in juvenile systemic lupus erythematosus. Lupus. 2005;14:152–158
  10. Tsokos GC, Kammer GM. Molecular aberrations in human systemic lupus erythematosus. Molecular Medicine Today. 2000;6:418–424
  11. Tsao BP, Wallace DJ. Genetics of systemic lupus erythematosus. Current Opinion in Rheumatology. 1997;9:377–379
  12. McDonagh JE. The adolescent challenge. Nephrology, Dialysis, Transplantation. 2000;15:1761–1765
  13. Brunner HI, Gianni EH. Health-related quality of life in children with rheumatic diseases. Current Opinion in Rheumatology. 2003;15:602–612
  14. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism. 1997;40:1725
  15. Tan EM, Cohen AS, Fries JF, et al. The revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism. 1982;25:1271–1277
  16. Ferraz MB, Goldenberg J, Hilario MO, et al. Evaluation of the ARC lupus criteria data set in pediatric patients. Committees of Pediatric Rheumatology of the Brazilian Society of Pediatrics and the Brazilian Society of Rheumatology. Clinical and Experimental Rheumatology. 1994;12:689–690
  17. Shulman JD. Prevalence of oral mucosal lesions in children and youths in the USA. International Journal of Paediatric Dentistry. 2005;15:89–97
  18. Hilario MO, Len CA, Roja SC, et al. Frequency of antinuclear antibodies in healthy children and adolescents. Clinical Pediatrics. 2004;43:637–642
  19. Cainelli F, Betterle C, Vento S. Antinuclear antibodies are common in an infectious environment but do not predict systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2004;63:1707–1708
  20. Zimmerman SA, Ware RE. Clinical significance of the antinuclear antibody test in selected children with idiopathic thrombocytopenia purpura. Journal of Pediatric Hematology/Oncology. 1997;19:297–303
  21. Symmons DP, Coppock JS, Bacon PA, et al. Development and assessment of a computerised index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Quarterly Journal of Medicine. 1988;69:927–937
  22. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004: development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology. 2004;44:902–906
  23. Ruperto N, Ravelli A, Murray KJ, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology. 2003;42:1452–1459
  24. Ruperto N, Ravelli A, Cuttica R, et al. The Pediatric Rheumatology International Trials Organisation criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. Arthritis and Rheumatism. 2005;52:2854–2864
  25. Brunner HI, Jones OY, Lovell DJ, et al. Lupus headaches in childhood-onset systemic lupus erythematosus: relationship to disease activity as measured by the systemic lupus erythematosus disease activity index (SLEDAI) and disease damage. Lupus. 2003;12:600–606
  26. Marks SD, Pilkington C, Woo P, et al. The use of the British Isles Lupus Assessment Group (BILAG) index as a valid tool in assessing disease activity in childhood-onset systemic lupus erythematosus. Rheumatology. 2004;43:1186–1189
  27. Haines LJ, Saidi G, Cooke RW. Prevalence of severe fatigue in primary care. Archives of Disease in Childhood. 2005;90:367–368
  28. Olfat MO, Al-Mayouf SM, Muzaffer MA. Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus. Clinical Rheumatology. 2004;23:395–399
  29. Wyckoff PM, Miller LC, Tucker LB, et al. Neuropsychological assessment of children and adolescents with systemic lupus erythematosus. Lupus. 1995;4:217–220
  30. The American College of Rheumatology. Nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis and Rheumatism 1999; 42: 599–608.
  31. Govoni M, Castellino G, Padovan M, et al. Recent advances and future perspectives in neuroimaging in neuropsychiatric systemic lupus erythematosus. Lupus. 2004;13:149–158
  32. Falcini F, De Cristofaro MT, Ermini M, et al. Regional cerebral blood flow in juvenile systemic lupus erythematosus: a prospective SPECT study. The Journal of Rheumatology. 1998;25:583–588
  33. Hanly JG, Harrison MJ. Management of neuropsychiatric lupus. Best Practice and Research Clinical Rheumatology. 2005;19:799–821
  34. Hsu DT. Biological and psychological differences in the child and adolescent transplant recipients. Pediatric Transplantation. 2005;9:416–421
  35. McDaniel DH. Laser therapy of stretch marks. Dermatologic Clinics. 2002;20:67–76
  36. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the European Lupus Nephritis Trial, a randomised trial of low-dose versus high-dose cyclophosphamide. Arthritis and Rheumatism. 2002;46:2121–2131
  37. Cross J, Dwomoa A, Andrews P, et al. Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephron Clinical Practice. 2005;100:92–100
  38. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative nephritis. Hong Kong-Guangzhou Nephrology Study Group. The New England Journal of Medicine. 2000;343:1156–1162
  39. Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. Journal of the American Society of Nephrology. 2005;16:1076–1084
  40. Buratti S, Szer IS, Spencer CH, et al. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. Rheumatology. 2001;28:2103–2108
  41. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B cell therapy in systemic lupus erythematosus: pointing to the future. Current Opinion in Rheumatology. 2005;17:550–557
  42. Edelbauer M, Jungraithmayr T, Zimmerhackl LB. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report. Pediatric Nephrology. 2005;20:811–813
  43. Jayne D, Passweg J, Marmont A, et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus. 2004;13:168–176
  44. Silva CA, Leal MM, Leone C, et al. Gonadal function in adolescent and young women with juvenile systemic lupus erythematosus. Lupus. 2002;11:419–425
  45. Huong du L, Amoura Z, Duhaut P, et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide. a study of 84 patients. The Journal of Rheumatology. 2002;29:2571–2576
  46. Riley P, Maillard SM, Wedderburn LR, et al. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology. 2004;43:491–496
  47. Silva CA, Hallak J, Pasqualotto FF, et al. Gonadal dysfunction in male adolescents and young males with juvenile onset systemic lupus erythematosus. The Journal of Rheumatology. 2002;29:2000–2005
  48. Lakasing L, Khamashta M. Contraceptive practices in women with systemic lupus erythematosus and/or antiphospholipid syndrome: what advice should we be giving?. The Journal of Family Planning and Reproductive Health Care. 2001;27:7–12
  49. Ognenovski VM, Marder W, Somers EC, et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. The Journal of Rheumatology. 2004;31:1763–1767
  50. Moss KE, Iaonnou Y, Sultan SM, et al. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for two decades. Annals of the Rheumatic Diseases. 2002;61:409–413
  51. Tucker LB. Controversies and advances in the management of systemic lupus eryhtematosus in children and adolescents. Best Practice and Research Clinical Rheumatology. 2002;16:471–480
  52. Brunner HI, Silverman ED, To T, et al. Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis and Rheumatism. 2002;46:436–444
  53. Brunner HI, Feldman BM, Urowitz MB, et al. Item weightings for the systemic lupus erythematosus international collaborating clinics/American College of Rheumatology disease damage index using Rasch analysis do not lead to an important improvement. The Journal of Rheumatology. 2003;30:292–297
  54. Gladman DD, Urowitz MB. The SLICC/ACR damage index: progress report and experience in the field. Lupus. 1999;8:632–637
  55. Stoll T, Seifert B, Isenberg DA. SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. British Journal of Rheumatology. 1996;35:248–254
  56. Rahman P, Gladman DD, Urowitz MB, et al. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus. 2001;10:93–96
  57. Stoll T, Sutcliffe N, Mach J, et al. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus—a 5-yr prospective study. Rheumatology. 2004;43:1039–1044
  58. Moorthy LN, Robbins L, Harrison MJ, et al. Quality of life in paediatric lupus. Lupus. 2004;13:234–240
  59. Leong KP, Kong KO, Thong BYH, et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology. 2005;44:1267–1276
  60. Rinaldi S, Doria A, Salaffi F, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact of age. Rheumatology. 2004;43:1574–1579
  61. Doria A, Rinaldi S, Ermani M, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology. 2004;43:1580–1586
  62. Khanna S, Pal H, Pandey RM, et al. The relationship between disease activity and quality of life in systemic lupus erythematosus. Rheumatology. 2004;43:1536–1540
  63. Wajed J, Ahmed Y, Darlington PN, et al. Prevention of cardiovascular disease in systemic lupus erythematosus—proposed guidelines for risk factor management. Rheumatology. 2004;43:7–12
  64. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis and Rheumatism. 2001;44:2331–2337
  65. Urowitz MB, Feletar M, Bruce IN, et al. Prolonged remission in systemic lupus erythematosus. The Journal of Rheumatology. 2005;32:1467–1472
  66. Fessler BJ, Alarcóon GS, McGwin G, et al. Systemic lupus erythematosus in three ethnic groups. XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis and Rheumatism. 2005;52:1473–1480
  67. Jury EC, Ehrenstein MR. Statins: immunomodulators for autoimmune rheumatic disease?. Lupus. 2005;14:192–196
  68. Lakshminarayanan S, Walsh S, Mohanraj M, et al. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. The Journal of Rheumatology. 2001;28:102–108
  69. Yee C-S, Crabtree N, Skan J, et al. Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2005;64:111–113
  70. Bultink IEM, Lems WF, Kostense PJ, et al. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis and Rheumatism. 2005;54:2044–2050
  71. Trapani S, Civinini R, Ermini M, et al. Osteoporosis in juvenile systemic lupus erythematosus: a longitudinal study of the effect of steroids on bone mineral density. Rheumatology International. 2001;18:45–49
  72. Geusens PP, de Nijs RNJ, Lems WF, et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch society for Rheumtology. Annals of the Rheumatic Diseases. 2004;63:324–325
  73. Sambrook PN. How to prevent steroid induced osteoporosis. Annals of the Rheumatic Diseases. 2005;64:176–178
  74. Royal College of Paediatrics and Child Health. Bridging the gaps. Healthcare for adolescents; 2003.

PII: S1521-6942(05)00126-9

doi: 10.1016/j.berh.2005.11.003

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 2 , Pages 353-368 , April 2006

Article Tools